Small Bowel Bacterial Overgrowth Associated with Persistence of Abdominal Symptoms in Children Treated with a Proton Pump Inhibitor

• Published in: The Journal of pediatrics Vol. 166; no. 5; pp. 1310 - 1312.e1
• Main Authors: Sieczkowska, Agnieszka, MD, Landowski, Piotr, MD, PhD, Zagozdzon, Pawel, MD, PhD, Kaminska, Barbara, MD, PhD, Lifschitz, Carlos, MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-05-2015
• Subjects: Abdominal Pain - diagnosis; Adolescent; Breath Tests; Child; Child, Preschool; Female; Flatulence; Gastrointestinal Diseases; Humans; Hydrogen - chemistry; Intestine, Small - microbiology; Male; Microbiota; Pediatrics; Prospective Studies; Proton Pump Inhibitors - adverse effects; Proton Pump Inhibitors - therapeutic use; Methane; GI; Hydrogen; BH; Breath hydrogen; CH 4; GBHT; PPI; Gastrointestinal; Proton pump inhibitor; SBBO; H 2; Small bowel bacterial overgrowth; Glucose breath hydrogen test; H2; CH4
• ISSN: 0022-3476; 1097-6833
• DOI: 10.1016/j.jpeds.2015.01.004

Small bowel bacterial overgrowth (SBBO) was diagnosed in 22.5% of 40 children treated for 3 months with a proton pump inhibitor (PPI). Compared with those without SBBO, children with SBBO had higher frequency of abdominal pain, bloating, eructation, and flatulence. Patients with gastrointestinal symptoms after PPI treatment should be evaluated for SBBO rather than empirically prolonging PPI therapy.